News

News

WIB_icon

Rates of Myeloid Neoplasms in Patients With Unexplained Cytopenias

Patients with unexplained cytopenias may never receive a definitive diagnosis, or may eventually be classified as having myelodysplastic syndromes (MDS, a myeloproliferative neoplasm ...
WIB_icon

Enoxaparin Increases Risk of Intracranial Hemorrhage in Patients With Glioma

Venous thromboembolism occurs in approximately one-third of patients with glioma, but the decision to treat patients with anticoagulation is complicated by the risk for...
WIB_icon

CD19-Directed CAR T-Cell Therapy Associated With High Rates of MRD Negativity in Young Patients...

Though CD19-directed chimeric antigen receptor (CAR) T-cell therapies have shown great promise for the treatment of hematologic malignancies, the possibility of routinely bringing these...

Remembering Neil Abramson, MD, AACC Announces Clinical Chemistry Trainee Council Educational Initiative, and more

Remembering Neil Abramson, MD (1937-2017) Neil Abramson, MD, a hematologist/oncologist who served as a Blood Special Section Editor from 2008-2012, passed away at the age...

Pomalidomide Does Not Significantly Improve RBC Transfusion Needs in Myelofibrosis

Anemia occurs commonly in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF), and such patients are often red blood cell (RBC) transfusion-dependent. No therapy approved...

Finding the Best VTE Prophylaxis Options for Patients Undergoing Total Hip and Knee Replacement

For prophylaxis against venous thromboembolism (VTE) after total hip replacement (THR) or total knee replacement (TKR), guidelines from the American College of Chest Physicians...

CMS Proposes Public Reporting of Medical Facility Inspections

A new rule from CMS proposes increasing transparency of the inspection process of medical facilities by requiring that private health-care accreditors (the largest of...

PubMed to Disclose Funding Information of Studies Up Front

In March, the National Library of Medicine (NLM) implemented a series of changes to how conflict-of-interest (COI) information is displayed in PubMed-indexed abstracts. COI...

CTL019 Being Reviewed for DLBCL and ALL

The U.S. Food and Drug Administration (FDA) granted breakthrough-therapy designation for CTL019, a chimeric antigen receptor T-cell therapy, for adult patients with relapsed/refractory diffuse large...

FDA Lifts REMS Requirement for ESAs for Anemia

The U.S. Food and Drug Administration (FDA) has lifted its risk evaluation and mitigation strategy (REMS) certification requirement for erythropoiesis-stimulating agents (ESAs), specifically epoetin...
Advertisement

Current Issue

July 2017, Volume 3, Issue 8

This issue features an interview with the FDA's Richard Pazdur, highlights from the 2017 ASCO Annual Meeting, a debate about minimal residual disease in myeloma, and more.